Defining the molecular and cellular roots of lung cancer relapse after initial treatment remains an imperative to improve survival. Here we report that the lung stem cell marker Lgr6 becomes enriched in non-small cell lung cancer (NSCLC) cells during malignant progression. Lgr6+ NSCLC cells displayed self-renewal and differentiation properties along with a higher tumorigenic potential. Mechanistic investigations suggested that a defective repression of the miR-17-92 gene cluster was responsible for evolution of a selection for outgrowth of Lgr6+ NSCLC cells. High levels of expression of miR-19 family members were found to target and downregulate levels of p38α kinase, providing a specific survival signal for Lgr6+ cells as mediated by increased Wnt/ß-catenin activity. Our results identify a specific stem-like cell population in NSCLC with increased malignant potential, the elucidation of which may enable earlier prognosis and possibly the development of more effective targeted treatments.
INTRODUCTION
Lung cancer is the major cause of cancer related deaths in western countries (1) . Early detection and surgery have proven to be the most effective ways to improve survival (2) . Important advances have been made in the last 20 years, with the detection of oncogenes and mutations linked to many lung cancer types. However, therapies applied using drugs directed to those molecules or related pathways have failed to significantly increase survival, especially in the most prevalent cancer types, e.g. lung adenocarcinoma (3) (4) (5) . Cancer relapse after radio-and chemo-therapy is the essential reason for reduced survival (6) . Previously, efforts have focused on investigating the cells and mechanisms involved in the resistance and later virulence of lung cancers after therapeutic treatments (7, 8) . Recent theories in cancer research consider the existence of cell populations with stem cell like properties in many cancer types (9, 10) . These cancer stem cells would be responsible for tumor maintenance and would harbor the potential to colonize other tissues as metastatic cells (11, 12) . These cells would also be especially resistant to drugs, and they would be selected during tumor progression, generating more aggressive and metastatic disease (13, 14) .
In this paper, we have studied the cellular and molecular mechanisms behind the development and progression of human lung adenocarcinoma. We have previously characterized a population of human lung cells with stem cell potential to differentiate into all bronchioalveolar lineages while being able to self-renew. These epithelial cells express the stem cell marker Lgr6 (Leucine-rich repeat-containing G protein-coupled receptor 6). Lgr6, and its homologous receptors, are amplifiers of Wnt signaling and are involved in maintaining stem cell self-renewal (15) . We have analyzed the contribution of Lgr6+ cells to human lung adenocarcinomas. We have observed that cells expressing Lgr6 are enriched from early to late stages of human lung adenocarcinomas malignancy.
These cells showed a disruption in the balance between the p38α and miR- pathways. p53 mutation prevents its repression of miR-17-92 expression (16) .
Crosstalk between signaling pathways and its role in cancer has been extensively reported elsewhere (17, 18) . Reduced p38α promotes activation of Wnt signaling and, in human lung cancer samples, we observed a correlation between a deficiency in p38α protein and increase of Wnt signaling, promoting Lgr6+ cells during cancer progression.
These findings provide a new tool for early prognosis of human lung adenocarcinomas.
We demonstrate how a novel specific population of cells, and their regulatory mechanisms, is linked and contribute to better understanding of the malignant progression of lung adenocarcinomas. This co-adjuvant process, in parallel to oncogenic mutations, helps select cells with a higher potential to perpetuate (self-renewal) and manipulate the microenvironment, facilitating colonization of foreign tissues (metastasis).
MATERIAL AND METHODS

Isolation and culture of human lung adenocarcinoma cells
Cultures were established from freshly isolated lung adenocarcinoma cells obtained from cancer patients undergoing tumor resection (Papworth hospital, UK). Approval by the Ethics Committee at Cambridge University and the Papworth Hospital was received. In both cases infectious virus was added to cells in the presence of 8 mg/ml polybrene (hexadimethrine bromide, Sigma) and incubated for 6 h.
Histology and immunostaining
Lung adenocarcinoma tissue samples and xenografts were fixed overnight at 4°C in 4% paraformaldehyde (PFA) and embedded in paraffin or OCT. Paraffin blocks were cut in 5 μm sections using a microtome. OCT blocks were cut in 10 μm sections using a cryostat microtome at -20°C. H&E staining was performed using a Leica Autostainer The Ventana Discovery (Ventana Medical Systems) automated system was used for immunohistochemistry (IHC) on paraffin and frozen sections. Ventana Cell Conditioning 1 solution (CC1) was used to perform antigen retrieval in all sections.
Antibody detection was performed using the DAB Map detection kit (Ventana, Cat. No: 760-124), sections were counterstained with haematoxylin using the Leica Autostainer system and mounted manually.
For immunofluorescent staining, sections were incubated in blocking buffer (PBS, 4% donkey serum, 1% Triton) for 1 h at room temperature. Primary antibodies were incubated overnight at 4°C. Sections were rinsed three times in PBS and incubated with secondary antibodies diluted at 1:1000 for 1 h at room temperature. Slides were mounted in Vectashield ® mounting media with DAPI.
Immunostaining quantification
The number of positively stained cells on sections was quantified using Cell Profiler software. Three or more biological replicates of different stages of human lung adenocarcinoma were used to obtain the average number of positive cells in randomly selected fields. The significance of quantitative data was tested using an unpaired, twotailed t-test. The standard deviation of the mean is represented in the graphs by error bars.
Western blotting
Cells were lysed in lysis buffer (50 mM Tris-HCl pH 7. (Santa Cruz, sc-99123), α-tubulin (Sigma, T9026), P-GSK3 (Cell Signaling, #9323).
Total RNA isolation and quantitative RT-PCR.
Total RNA was extracted from cells or tissue using miRVana miRNA isolation kit Expression of all other genes was quantified using SYBR Green technology and normalized to a housekeeping gene (GAPDH or HPRT), using specific primers ( Table   1 ). Specificity of PCR products was tested by dissociation curves.
Flow cytometry
Single-cell FACS (MoFlo, Beckman Coulter) was performed following one hour incubation with anti-Lgr6 (Santa Cruz, sc-99123) and one hour in the dark with antiRabbit PE secondary antibody (Santa Cruz, sc-3745). 
Cell proliferation assay
In 24-well plates, 4x10 5 cells per well were plated in triplicates in general culture conditions. The number of viable cells was counted every day for 6 days using an automated Vi-CELL cell counter (Beckman-Coulter, Cat. No: 731050).
Mouse experiments
All mouse experiments were subjected to ethical approval and performed according to United Kingdom Home Office Regulations. CD-1 nude and NOD/SCID mice (Charles River) were maintained under standard pathogen-free conditions.
Subcutaneous injections
Freshly isolated lung adenocarcinoma cells were resuspended in 100 μl of Cells were injected under the skin of 6 to 8 week old nude or NOD/SCID mice with a 0.5 ml syringe. Mice were killed 10 to 12 weeks later. Subcutaneous growths were removed and prepared for histology sections.
Tail vein injections
NOD/SCID male mice were warmed for a few minutes, to induce vasodilatation, in a heated IVC recovery chamber set at 40°C. Mice were then put in a restraint tube and the tail cleaned using warm surgical scrub and water. A single-cell suspension of freshly isolated lung adenocarcinoma cells following FACS sorting, was resuspended in 100 μl PBS following FACS sorting and injected into the tail vein using a 30G needle and 1 ml syringe. Mice were killed 10 to 12 weeks later. Lungs were removed and prepared for histology sections.
RESULTS
We have described a population of human lung cells with the potential to differentiate both, in vitro and in vivo, into all mature bronchioalveolar cell types. These cells specifically express the membrane marker Lgr6 (16) . In mouse lung cancer models, bronchioalveolar stem cells are expanded during adenocarcinoma transformation (19, 20) . We studied the expression of the human bronchioalveolar stem cell marker Lgr6 in human lung adenocarcinomas. The adenocarcinoma origin of the tumors was confirmed as TTF1+/p63-to discard any tumors of squamous origin (Suppl. Fig. 1 ).
Accumulation of Lgr6 positive cells during human lung adenocarcinoma progression
We have analyzed 53 human lung cancers for the expression of a number of lung specific, cancer, and stem cell markers in samples of lung small cell, squamous and 1a ). Lgr6 expression in both earlier (Stage 1, Stage 2) or later (Stages 3, 4 and metastatic) disease was specifically localized to the tumor area, being absent from the surrounding healthy tissue (Fig. 1a) . There was a direct correlation between adenocarcinoma stage and Lgr6 expression levels in tumor samples, as observed by protein expression (Fig. 1b) . Analysis of cell populations from different stage adenocarcinomas by flow cytometry confirmed the increase in the Lgr6+ population during tumor progression and was shown to be particularly enriched after Stage 2 ( 
Selection of Lgr6 cells with a disrupted p38α/miR-17-92 axis
We have previously shown that human lung Lgr6+ stem cells are regulated by a fine tuned regulated crosstalk between the p38α MAPK pathway and the microRNA cluster miR-17-92 (16) . In addition, miR-17-92 has been reported to be overexpressed in lung tumors (21, 22) . Analysis of miR-17-92 expression by qPCR in tumors from different adenocarcinoma stages confirmed the increased expression of the cluster members during cancer progression (Fig. 2a) . We have previously shown that expression of the miR-17-92 cluster is transcriptionally repressed by p53 (16 immunohistochemistry showed that nuclear p53 is lost during adenocarcinoma progression correlating with higher miR-17-92 levels (Fig. 2b) . In addition, enhanced miR-17-92 expression correlated with decreased levels of p38α in late stage adenocarcinomas, when compared to their early stage counterparts (Fig. 2c). p38α protein, but not mRNA expression, has been shown to be reduced in human lung tumors (20) . Hence, downregulation of p38α must be a post-transcriptional event. Using public databases (www.targetscan.org), we noted that p38α was a putative target for one of the miR-17-92 members, miR-19. Using a lentiviral vector in cultured lung Lgr6+ cells, we observed that miR-19 overexpression induces proliferation (Suppl. Fig. 2a, b) . miR-19 specific targeting of p38α 3'-UTR was shown using a luciferase reporter assay (Suppl. Fig. 2C) , and results in decreased p38α protein (Fig. 2d) . This is a previously unreported negative crosstalk regulation and it creates a negative feedback loop between the miR-17-92 and p38α pathways (Suppl. Fig. 2d ).
Repression of p38α is enhanced in Lgr6+ cells from Stage 2 tumors, when compared to counterpart Lgr6-cells (Fig. 2e) . Reduced p38α protein in Lgr6+ correlates with a change in the expression of miR-17-92 members, larger than its increase in Lgr6-cells, during cancer progression (Fig. 2f) .
p38 regulates the expression of Wnt signaling components
Wnt signaling is a key pathway related to cancer development is (23) . Inhibitory phosphorylation of GSK3 and nuclear translocation of β-Catenin are hallmarks of canonical Wnt signaling and are present in many cancers (24, 25) . We observed increased P-GSK3 levels with increasing lung adenocarcinoma stage (Fig. 3a) .
Activation of the canonical Wnt pathway and enhanced signal was confirmed by immunohistochemistry, showing specific P-GSK3 and nuclear β-Catenin induction in (Fig. 3b) . Further confirmation was established by qPCR analysis of mRNA expression of Wnt components with elevated levels of enhancers (Lrp6) and targets (Lef1, Tcf4, Axin2) and reduced levels of Wnt repressors (Wif1, Gremlin, Dkk1, Dab2) in late stages (Fig. 3c and Table 1 ).
Lgr6 is a promoter of Wnt receptor signaling. The co-activator Lrp6 interacts with Lgr6 enhancing the response to Wnt ligands, amplifying the receptors signal (26, 27 (Fig. 3d and Suppl. Fig. 3 ).
Using inactivating phospho-GSK3 (Ser9) as a sensor of Wnt signal, we observed that normal lung Lgr6+ cells, deficient in p38α (p38KD), showed an increase in P-GSK3. This is independent of miR-17-92, as combined downregulation of this pathway (p38KD/shmiR) failed to rescue Wnt activation (Fig. 3e) . Loss of p38α modified the expression of other components of the Wnt pathway. Interestingly, p38α-deficient Lgr6+ lung cells showed an increased expression of the Wnt co-receptor Lrp6 and decreased of the Wnt antagonist DKK1 (Fig. 3f) . Inactivation of GSK3 correlates with augmented expression of genes regulated by canonical Wnt, confirming the enhanced activation of the pathway in Lgr6+ cells lacking p38α (Fig. 3g) . The specific role of p38α as a negative regulator of canonical Wnt signaling in Lgr6+ cells was confirmed by overexpression of p38α in Lgr6+/p38KD cells, restoring the P-GSK3 to control levels (Fig. 3h) . Partial rescue, by p38α overexpression, was confirmed by qPCR analysis with significant reduction of Wnt targets and increase in Wnt repressors (Fig.   3i ). Fig. 1b ) and epithelial markers (Suppl. Fig. 4a, b, c) , while increasing Lgr6+ cell numbers in later malignant stages (Suppl. Fig. 4e ).
Selected Lgr6 cells have cancer stem cell like properties
To test some of the tumorigenic and stem-like properties of the Lgr6+ cells, we sorted cells from different stages of lung adenocarcinoma. Both Lgr6-and Lgr6+ tumor cells express lung markers at similar levels lung markers (Fig. 4a) . Interestingly, only the marker AQP5 (aquaporin 5) is overexpressed in Lgr6+ tumor cells. This protein is a marker for lung cancer malignancy and has been reported that overexpression links lung cancer with tumor invasion, proliferation and metastatic features (30, 31).
In culture, cells from later stages showed an increase in proliferation, expanding at higher rates (Suppl. TTF1 and a human specific mitochondrial antibody (Fig. 4c) . Interestingly, Stage 2 Lgr6+ tumor cells retained differentiation potential. The tumor masses formed from injected Lgr6+ human tumor cells were only partially positive for Lgr6 whereas they expressed lung specific markers such as SP-C or CC-10 (Fig. 4d) . This confirms a putative cancer stem cell role for Lgr6+ human lung adenocarcinoma cells. We recapitulated the tumors formed by Lgr6+ cancer cells using normal Lgr6+ lung cells transformed by overexpression of oncogenic K-RasG12D. These cells co-expressed GFP and could be visually traced (green) in the lung tumors (Suppl. Fig. 5a ).
Histological analysis showed features similar to those from Lgr6+ adenocarcinoma cells (Suppl. Fig. 5b ), and they expressed GFP and the adenocarcinoma markers TTF1 and CK7 but not the squamous carcinoma marker p63 (Suppl. Fig. 5c ). Immunofluorescent staining confirmed the human origin of the tumors formed by Lgr6+ transformed lung cells and the adenocarcinoma features, as they expressed TTF1 (Suppl. Fig. 5d ). (Fig. 5a ). As has been previously observed in IV injections, Lgr6-cells failed to form subcutaneous tumors. Tumors from Lgr6+ cells were histologically analyzed (Fig. 5a) . The human lung adenocarcinoma origin of the resected tumors was confirmed, with expression of TTF1 and human mitochondrial antigen evident (Fig. 5b) . Further analysis by immnuofluorescent staining revealed the loss of epithelial (E-Cad) and the gaining of stem cell (Lgr6) markers during the progression from early to late stage disease ( 
DISCUSSION
Despite all of the advances in unraveling the molecular and biological initiation and progression of cancer (32, 33), the knowledge of these processes in lung adenocarcinoma is still poor, resulting in little improvement in patient survival (5) .
In this manuscript, we revealed the potential of a population of human lung adenocarcinoma cells, characterized for expressing Lgr6, that are selected through the progression of the cancer and that harbor cancer stem cell like properties. As a consequence of p53 mutating inactivation, there is a dysregulation of the balance between two pathways, the miR-17-92 family of microRNAs and the p38α kinase, that control normal homeostasis in human Lgr6+ lung stem cells. Lack of p53 leads to loss of its repressive effects on miR-17-92 cluster expression. miR-17-92 overexpression is a common feature in lung cancer. We have now shown that a miR-17-92 member, miR-19, downregulates p38α.
We have previously reported a deficiency in p38α protein in human lung cancer (20) .
There is some evidence of an inhibitory role of p38α on Wnt signaling (31, 34). Here 
we have found that p38α deficiency results in a wide-ranging dysregulation of Wnt components, repression of Wnt inhibitors and promotion of its enhancers.
Wnt signaling is a regulator of stem cell self-renewal and a signature pathway in many cancers (15) . One of the components overexpressed in the absence of p38α is the Lowdensity lipoprotein-related receptor 6 (LRP6), which plays a central role in canonical Wnt signal (26, 35) . We have demonstrated the specificity of this p38α function, as it can be rescued by recovering p38α expression. LRP6 function can be enhanced by interacting with R-spondin receptors like Lgr6 (27) . Cells expressing Lgr6 can respond to Wnt activation, enhancing the canonical signal and, hence, promoting growth. Similar to other related R-spondins (e.g. Lgr5), Lgr6 is also considered a marker for adult stem cells and a potential marker for cancer stem cells (27) . We now show that 
